vorinostat has been researched along with Carcinoma, Mucoepidermoid in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Carcinoma, Mucoepidermoid: A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wagner, VP | 1 |
| Martins, MD | 1 |
| Martins, MAT | 1 |
| Almeida, LO | 1 |
| Warner, KA | 1 |
| Nör, JE | 1 |
| Squarize, CH | 1 |
| Castilho, RM | 1 |
1 other study available for vorinostat and Carcinoma, Mucoepidermoid
| Article | Year |
|---|---|
Targeting histone deacetylase and NFκB signaling as a novel therapy for Mucoepidermoid Carcinomas.
Topics: Antineoplastic Agents; Carcinoma, Mucoepidermoid; Cell Line, Tumor; Emetine; Histone Deacetylase Inh | 2018 |